Logo

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

Share this

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

Shots:

  • The P-III DAPA-HF study involves assessing of Farxiga (10mg- qd) vs PBO in patients with heart failure and reduced ejection fraction (HFrEF) (LVEF ≤ 40%)- with/without type-2 diabetes on the addition to SOC including ACE inhibitors- ARB- MRAs- beta-blockers and neprilysin inhibitors
  • The P-III DAPA-HF study resulted in meeting its 1EPs i.e- reduction in cardiovascular death or worsening of heart failure
  • Farxiga is an oral SGLT2 inhibitor- indicated as both monothx. and combination therapy to improve glycemic control- reduction in weight & blood pressure as an adjunct to diet and exercise in patients with T2D- also being studied in patients with HF in DELIVER and DETERMINE (HFrEF and HFpEF) trials respectively

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions